Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Immunology Biosimilars Market?

The market size for immunology biosimilars has seen swift expansion in the past few years. Its projected growth from $7.38 billion in 2024 to $8.35 billion in 2025, forecasts a compound annual growth rate (CAGR) of 13.1%. Factors contributing to growth during the historic period include the escalating adoption of biosimilars, a surge in demand for cost-effective biologics, a growing number of autoimmune disease cases, heightened patient knowledge about biosimilar treatments, and amplified regulatory backing for biosimilar approval.

The market size of immunology biosimilars is predicted to experience a swift expansion in the upcoming years, expanding to $13.57 billion by 2029 with a compound annual growth rate (CAGR) of 12.9%. Multiple factors driving the growth during forecasted period include an increased emphasis on minimizing healthcare costs, a surge in chronic inflammatory conditions, an extended reach in emerging markets, heightened endorsement for biosimilar interchangeability, and increased investments by pharmaceutical firms. The future trend is likely to encompass enhancements in biologics manufacturing technology, partnerships in research and development, the emergence of next-generation biosimilars, advancements in delivery mechanisms, and the incorporation of artificial intelligence in biosimilar development.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25789&type=smp

What Drivers Are Accelerating Expansion Of The Immunology Biosimilars Market?

The escalating rise of chronic immunological disorders is anticipated to fuel the expansion of the immunology biosimilars market. These disorders are constant conditions where the immune system either attacks the body’s tissues or falls short in its protection. The increase in these disorders can be attributed to a growing number of individuals suffering from prolonged immune system disorders that necessitate sustained treatment, active management of the disease, and consistent healthcare support. Immunology biosimilars aid these chronic conditions by offering cost-effective treatment options that bolster long-term disease control and enhance patient accessibility to crucial therapies that regulate immune system malfunctions. For example, the Australian Institute of Health and Welfare, a government institution based in Australia, reported in June 2024 that rheumatoid arthritis, a systemic autoimmune disease, impacted an estimated 514,000 people, translating to 2.0% of the population in 2022. Of these, 2.5% were females and 1.6% were males affected by the disease. Hence, the growing incidence of chronic immunological conditions is triggering an upsurge in the immunology biosimilars market.

What Are The Primary Segmentation Parameters In The Immunology Biosimilars Market?

The immunology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators

2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents, Anti-Interleukin-6 Agents, Anti-Cluster of Differentiation 20 Agents, Anti-Interleukin-12/23 Agents, Other Monoclonal Antibodies

2) By Fusion Proteins: Etanercept Biosimilars, Other Fusion Protein Biosimilars

3) By Recombinant Proteins: Recombinant Human Insulin, Recombinant Human Growth Hormone, Recombinant Human Erythropoietin, Other Recombinant Protein Biosimilars

4) By Interferons: Interferon Alpha, Interferon Beta, Interferon Gamma

5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors, Janus Kinase Inhibitors, Other Immunomodulatory Biosimilars

Which Emerging Trends Are Reshaping The Immunology Biosimilars Market Landscape?

The immunology biosimilars market is seeing a trend where leading companies are focusing on developing the next generation of biosimilar innovations. They are focussing on future interchangeability designation, novel delivery systems and improved formulations with increased stability. This is designed to provide a more effective and accessible range of treatment options for patients. Future interchangeability designation indicates a biosimilar’s potential to meet regulatory standards, allowing pharmacy-level substitution for the reference biologic without intervention from the prescribing authority. For example, in February 2025, Sandoz Group AG, a Swiss-based pharmaceutical firm, introduced Pyzchiva (ustekinumab-ttwe), a biosimilar to Stelara. It’s used for treatment of several chronic autoimmune disorders such as plaque psoriasis, Crohn’s disease, ulcerative colitis and psoriatic arthritis. The launch was accomplished in collaboration with the South Korea-based biopharmaceutical firm, Samsung Bioepis Co. Ltd. This reinforces Sandoz’s pledge to broaden access to immunology biosimilars, offering a cost-effective treatment option centred around the patient with enhanced stability, multiple dosage options and the unique capability to be re-cooled following initial refrigeration.

Which Players Are Shaping The Competitive Landscape Of The Immunology Biosimilars Market?

Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Stada Arzneimittel AG, Cipla Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/immunology-biosimilars-global-market-report

What Are The Emerging Regional Trends Driving The Immunology Biosimilars Market?

North America was the largest region in the immunology biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25789&type=smp

Browse Through More Reports Similar to the Global Immunology Biosimilars Market 2025, By The Business Research Company

Automated Immunoassay Analyzers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/automated-immunoassay-analyzers-global-market-report

Immunoassay Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Immunohematology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunohematology-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model